SCHEMBL4559549

SCHEMBL4559549

CC(=O)C(C(N)=O)(c1ccccc1)N1CCNCC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.41
MAPT P10636 2/20 0.41
SIGMAR1 Q99720 2/20 0.41
OPRD1 P41143 3/20 0.39
CHRM2 P08172 6/20 0.38
CHRM3 P20309 6/20 0.38
ALDH1A1 P00352 3/20 0.38
CHRM1 P11229 2/20 0.38
MEN1 O00255 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
CHRM4 P08173 1/20 0.38
CHRM5 P08912 1/20 0.38
POLB P06746 1/20 0.37
USP2 O75604 1/20 0.37
TSHR P16473 1/20 0.37
HSD17B10 Q99714 1/20 0.37
HPGD P15428 1/20 0.35
ABCC1 P33527 1/20 0.35
HTT P42858 1/20 0.35
HTR3E A5X5Y0 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4559545 0.77 SIGMAR1 (0.44) KMT2AMAPTSIGMAR1OPRD1CHRM2
SCHEMBL4558587 0.76 SIGMAR1 (0.42) KMT2AMAPTSIGMAR1OPRD1CHRM2
SCHEMBL632161 0.76 SIGMAR1 (0.42) KMT2AMAPTSIGMAR1OPRD1CHRM2
SCHEMBL4557805 0.76 SIGMAR1 (0.42) KMT2AMAPTSIGMAR1OPRD1CHRM2
SCHEMBL4558785 0.75 KMT2A (0.40) KMT2AMAPTSIGMAR1OPRD1CHRM2
SCHEMBL4558669 0.75 CHRM3 (0.41) KMT2AMAPTSIGMAR1OPRD1CHRM2
SCHEMBL4899599 0.74 CHRM3 (0.40) KMT2AMAPTSIGMAR1OPRD1CHRM2
SCHEMBL4559921 0.72 SIGMAR1 (0.40) KMT2AMAPTSIGMAR1OPRD1CHRM2
Hydrochloric Acid SCHEMBL8483088 0.72 KMT2A (0.40) KMT2AALDH1A1MEN1SMN1; SMN2POLB
SCHEMBL18284663 0.72 SIGMAR1 (0.45) KMT2AMAPTSIGMAR1OPRD1CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7501407-B2 Pyrimidine A2B selective antagonist compounds, their synthesis and use OSI PHARMACEUTICALS, INC. (US) 2009-03-10 US disclosed
US-6916804-B2 Pyrimidine A2b selective antagonist compounds, their synthesis and use OSI PHARMACEUTICALS, INC. (US) 2005-07-12 US disclosed
US-20050119271-A1 Pyrimidine A2B selective antagonist compounds, their synthesis and use OSI PHARMACEUTICALS, INC. 2005-06-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050119271-A1 Pyrimidine A2B selective antagonist compounds, their synthesis and use ADORA2B, ADORA2A, ADORA3 KMT2A 2079/4885MAPT 1930/4885SIGMAR1 218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.